Price
No data yet.
Social Signal Score
Analyst Ratings
35 analystsRevenue
$31.91M-45.95%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert I. Blum
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 673
- Beta
- 0.36
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -1.25
Financials
Revenue
$31.91M-46.0%Net Income
$-198.76M-695.8%EBITDA
$-191.75M-661.6%Free Cash Flow
$-164.17MEPS (diluted)
$-1.50-302.7%Shares Outstanding (diluted)
132.09M+205.6%Operating Expenses
$202.20MCash & Debt
$1.17BReturn of Capital
$0.00Revenue by Segment (annual)
$8.69MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $88.04M | $-784.96M | $-6.54 |
| 2024 | $18.47M | $-589.53M | $-5.26 |
| 2023 | $7.53M | $-526.24M | $-5.45 |
| 2022 | $94.59M | $-388.95M | $-4.33 |
| 2021 | $70.43M | $-215.31M | $-2.80 |
| 2020 | $55.83M | $-127.29M | $-1.97 |
| 2019 | $26.87M | $-121.69M | $-2.59 |
| 2018 | $31.50M | $-106.29M | $-1.95 |
| 2017 | $13.37M | $-127.79M | $-2.59 |
| 2016 | $106.41M | $16.45M | $0.41 |
| 2015 | $28.66M | $-37.50M | $-0.97 |
| 2014 | $46.94M | $-14.65M | $-0.41 |
| 2013 | $30.65M | $-33.72M | $-1.24 |
| 2012 | $7.56M | $-41.68M | $-2.15 |
Valuation
CYTKhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (22)
- Newsglobenewswire.com·4d ago·Neutral
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026 SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations, including two Late Breaking Clinical Research presentations and two oral presentations, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 taking place in Phoenix, AZ from October 9 – 12, 2026.
View source ↗ - Newsglobenewswire.com·6d ago·Positive
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice
View source ↗ - Newsmarketbeat.com·10d ago·Neutral
Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference Cytokinetics NASDAQ: CYTK executives outlined the company's commercial expansion plans, cardiovascular pipeline and business-development priorities during a Bernstein investor symposium, highlighting the launch of MYQORZO and clinical programs targeting several forms of heart failure.
View source ↗ - News (RSS)yahoo·12d ago·Neutral
Cytokinetics (CYTK): Can Myqorzo Growth Create a New Biopharma Success Story?
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
… Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2026 it granted stock options to purchase an aggregate of 52,834 shares of common stock and 35,025 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 23 employees, whose employment commenced in August and September 2026 as a material inducement to …
View source ↗ - Newsseekingalpha.com·21d ago·Positive
Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·22d ago·Positive
Cytokinetics: Why Myqorzo Doesn't Make Me A Buyer Yet Cytokinetics, Incorporated's stock remains under pressure. At the same time, Myqorzo sales rose 427.1% quarter-over-quarter to $25.3 million in the second quarter, despite competitive pressure from Bristol Myers Squibb's Camzyos. Meanwhile, the August 28 NEJM article revealed full Phase 3 ACACIA-HCM data, in which Myqorzo showed high efficacy in treating symptomatic nonobstructive HCM, where Camzyos failed.
View source ↗ - Newsglobenewswire.com·22d ago·Neutral
Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program Program Provides Communications and Outreach Support for Patient Advocacy Organizations Focused on Cardiovascular Diseases
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Cytokinetics, Incorporated (CYTK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Cytokinetics, Incorporated (CYTK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newszacks.com·33d ago·Neutral
Can CYTK's Aficamten Strengthen Its HCM Growth Prospects? Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.
View source ↗ - Newsglobenewswire.com·37d ago·Positive
…Across Pre-Trial Treatment Groups in Patients with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Aug. 29, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from ACACIA-HCM (Assessment Comparing A ficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) and MAPLE-HCM ( M etoprolol vs A ficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) were presented in a Late Breaking Clinical Session at the European…
View source ↗ - Newsseekingalpha.com·38d ago·Positive
Cytokinetics, Incorporated (CYTK) Discusses Positive Phase III Results From ACACIA-HCM Trial of Aficamten in Nonobstructive HCM Transcript Cytokinetics, Incorporated (CYTK) Discusses Positive Phase III Results From ACACIA-HCM Trial of Aficamten in Nonobstructive HCM Transcript
View source ↗ - News (RSS)seekingalpha·38d ago·Negative
Cytokinetics posts full data from late-stage trial for lead drug in non-obstructive HCM
View source ↗ - Newsmarketbeat.com·38d ago·Positive
Cytokinetics' Aficamten Hits Dual Phase III Endpoints in Non-Obstructive HCM Cytokinetics NASDAQ: CYTK presented primary results from its Phase III ACACIA-HCM trial evaluating aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, or nHCM, reporting that the study met its dual primary endpoints for patient-reported health status and exercise capacity.
View source ↗ - Newsreuters.com·39d ago·Negative
Cytokinetics eyes expanded use of heart drug after promising late-stage data Cytokinetics said on Friday detailed late-stage data showed its drug, aficamten, significantly improved symptoms and exercise capacity in patients with a genetic heart condition that currently has no approved treatments.
View source ↗ - Newsglobenewswire.com·39d ago·Negative
…day at 2:00 PM Central European Summer Time (8:00 AM Eastern Time) SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (Assessment Comparing A ficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) were presented in a Hot Line Session at the Eu…
View source ↗ - News (RSS)yahoo·44d ago·Negative
Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700
View source ↗ - News (RSS)fool·44d ago·Negative
Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700 Blum exercised stock options at $10.60 and sold at $76.76, capturing significant appreciation.
View source ↗ - Newsfool.com·44d ago·Negative
Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700 The transaction involved the disposal of 7,500 shares. The disposition resulted in a 2% reduction in the insider's total equity holdings.
View source ↗ - Newsglobenewswire.com·47d ago·Positive
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
View source ↗ - Newszacks.com·47d ago·Positive
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock? Myqorzo's early launch momentum and global expansion could boost Cytokinetics, while pipeline progress may widen its growth opportunity.
View source ↗ - Newsglobenewswire.com·48d ago·Neutral
…s Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 14, 2026 it granted stock options to purchase an aggregate of 27,565 shares of common stock and 18,273 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 12 employees, whose employment commenced in July and August 2026 as a material inducement to their em…
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-1.45 per share
Typical surprise +2.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-1.50 vs $-1.63beat
- Tue, May 5$-1.67 vs $-1.67beat
- Tue, Feb 24$-1.50 vs $-1.48miss
- Wed, Nov 5$-2.55 vs $-1.59miss
- Thu, Aug 7$-1.12 vs $-1.34beat
- Tue, May 6$-1.36 vs $-1.41beat
Estimates and results for CYTK via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CYTK officers and directors.
- Bought
- —
- Sold
- $22.6m
0 trades
29 trades
- Blum Robert Isold
- Malik Fady Ibrahamsold
- Landry Robert Esold
- Blum Robert Isold
- Blum Robert Isold
- Landry Robert Esold
- Malik Fady Ibrahamsold
- Parshall B Lynnesold
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jul 3, 2026 (3d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Nov 18, 2025 (40d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (57d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (63d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.